CHOW KEN,HEIDELBAUGH TODD,GIL DANIEL,GARST MICHAEL,WHEELER LARRY A.,NGUYEN PHONG X.,GOMEZ DARIO G.
申请号：
PL37422303
公开号：
PL213028B1
申请日:
2003.05.16
申请国别(地区):
PL
年份:
2012
代理人:
摘要：
Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
